Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus K 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus K 8.
K-LEASE vs K+8
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Hypokalemia prevention and treatmentDigitalis intoxication with hypokalemia
Treatment of hypokalemiaPrevention of hypokalemia in patients at risk (e.g., diuretic therapy)Digitalis intoxication
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Not metabolized; renally excreted as potassium ion.
Not metabolized; primarily excreted unchanged by the kidneys via distal tubular secretion.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Not protein bound (0%). Potassium is a free ion.
<10% bound; primarily to albumin. Binding is negligible.
0.33 L/kg (total body water); clinical meaning: potassium distributes throughout total body water, but primarily intracellular (98% intracellular).
0.3-0.4 L/kg (adults); Vd decreases in neonates and increases in pregnancy.
Oral: 100% (as potassium chloride; fully absorbed).
Oral immediate-release: 85-95%; extended-release: 80-90% (dependent on formulation). IV: 100%.
GFR 20-49 mL/min: reduce dose by 50%; GFR <20 mL/min: contraindicated.
GFR >50 mL/min: no adjustment; GFR 30-50 mL/min: reduce dose by 25-50%; GFR <30 mL/min: avoid use or reduce dose by 50-75% with close monitoring.
Child-Pugh A: no adjustment; Child-Pugh B/C: contraindicated due to risk of encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose by 25%; Child-Pugh C: avoid use or reduce dose by 50% with monitoring.
1-3 mEq/kg/day in divided doses with meals; maximum 3 mEq/kg/day.
0.5-1 mEq/kg intravenously per dose, not to exceed 1 mEq/kg/hour; or 1-3 mEq/kg/day orally divided 2-3 times daily.
Start at lower end of dosing range (25 mEq/day) due to decreased renal function and increased sensitivity to hyperkalemia.
Initiate at low end of dosing range (20-40 mEq/day) due to age-related decline in renal function; monitor serum potassium and renal function closely.
None
Potassium chloride injection concentrate must be diluted before use; direct injection can cause fatal hyperkalemia.
["Hyperkalemia risk especially in renal impairment","Cardiac arrest if given too rapidly","Monitor serum potassium and ECG during administration"]
Monitor serum potassium levels; caution in renal impairment, cardiac disease, acidosis; risk of hyperkalemia; avoid rapid intravenous infusion; use with caution in patients receiving potassium-sparing diuretics.
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Adynamic ileus","Concurrent use with potassium-sparing diuretics"]
Hyperkalemia; severe renal impairment with oliguria or anuria; untreated Addison's disease; acute dehydration; extensive tissue breakdown (e.g., burns); concurrent use of potassium-sparing diuretics.
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes) unless directed. Consume low-potassium diet as advised. Do not take with calcium-containing foods or supplements; separate by at least 6 hours.
Avoid high-potassium foods (bananas, oranges, potatoes, spinach, avocados, tomatoes) if at risk of hyperkalemia. Limit intake of salt substitutes containing potassium chloride. Grapefruit juice may increase serum potassium; avoid excessive consumption.
FDA Pregnancy Category C. First trimester: limited human data, animal studies show potential for fetal harm; avoid unless benefit outweighs risk. Second trimester: risk of hypocalcemia and arrhythmias in fetus if maternal potassium abnormal. Third trimester: possible fetal hyperkalemia if maternal overdose; monitor neonatal potassium levels.
Potassium supplementation (K+8) is not teratogenic. Normal maternal potassium levels are essential for fetal development. Hypokalemia or hyperkalemia may pose risks. First trimester: No evidence of teratogenicity. Second/third trimester: Monitor for electrolyte imbalance; hyperkalemia can cause fetal arrhythmias.
Not recommended during breastfeeding. M/P ratio unknown. Insufficient human data; potential for adverse effects in nursing infant (e.g., hyperkalemia, arrhythmias).
Potassium is a normal component of breast milk. Supplementation in physiological doses does not pose risk to infant. M/P ratio: ~0.4-0.5 (similar to serum). No contraindication with breastfeeding.
No standard dose adjustments recommended. Monitor serum potassium closely; dose may need reduction due to increased plasma volume and GFR in pregnancy. Individualize based on potassium levels.
Dose adjustment not typically required in pregnancy due to pharmacokinetic changes. However, increased plasma volume increases potassium requirements; monitor for hypokalemia. Start at lower end of dosing range and adjust based on serum potassium levels.
Category C
Category C
K-LEASE (calcium polystyrene sulfonate) is a potassium-binding resin used for hyperkalemia. Administer orally or rectally; ensure bowel movements to avoid impaction. Monitor serum potassium frequently. Not for rapid correction of life-threatening hyperkalemia. Use with caution in patients with constipation or gastrointestinal surgery.
Administer slowly IV to avoid hyperkalemia; monitor ECG with infusion rates >10 mEq/h. Must be diluted in appropriate IV fluids; never give undiluted due to risk of cardiac arrest. Contraindicated in severe hyperkalemia (K+ >5.5 mEq/L) and advanced renal failure.
Take this medication exactly as prescribed, usually 1-4 times daily.Mix powder with water or juice as directed; do not take dry.Stay hydrated and report constipation, abdominal pain, or bloody stools.Do not use laxatives or antacids containing magnesium or aluminum without consulting your doctor.This medication works slowly; it is not for emergency potassium lowering.
Take potassium supplements exactly as prescribed; never double a missed dose.Avoid salt substitutes containing potassium without consulting your doctor.Report symptoms of hyperkalemia: muscle weakness, fatigue, irregular heartbeat, or tingling in hands/feet.Inform all healthcare providers that you are taking potassium supplements.Do not crush or chew extended-release tablets; swallow whole.